

Maryland Department of Health
MEMO: Allocation Scenario for Evusheld Long-Acting Antibody
December 20, 2021

Background

In November 2021, the COVID-19 Therapeutics team was tasked with surveying hospitals and to gauge their interest in participating in the program, as hospitals were the strongest touchpoints for patients with severe immunocompromised status.

All hospitals were contacted through Maryland Hospital Association, and follow-up calls were made to hospitals that did not respond. In total, the therapeutics team received 21 responses, with 20 sites indicating they would be interested in receiving an allocation of the Evusheld product. Hospitals from across Maryland are represented, such that each region has a site that is slated to offer the therapeutic.

New Therapeutic Approval: Evusheld

Evusheld (AstraZeneca) is a long-acting monoclonal antibody that received [emergency use authorization](#) (EUA) on December 8, 2021. It is indicated for use as follows:

- Individuals >12 years old and weighing at least 40kg
- Not currently infected with SARS-CoV-2 and not recently exposed to SARS-CoV-2
- Moderate to severe immune compromise due to medical condition or receipt of immunosuppressive medication/treatment AND may not mount adequate response to COVID-19 vaccination
- OR, for whom vaccination with any available COVID-19 vaccine is not recommended due to severe adverse reaction to vaccine or components.

Week 1 Allocation

Maryland was allocated 888 courses in week 1. Based on hospital's stated capacity and supply partners (for example, UMMS distributes to system hospitals), the therapeutics team suggested the following allocation breakdown:

Site Name	Allocation (Quantities of 24)	Region
Adventist White Oak Medical Center	24	Capital Region
Adventist Healthcare Takoma Park Campus (Alternate Care Site)	24	Capital Region
FrederickHealth Hospital	24	Capital Region
Luminis Health Doctors Community Medical Center	24	Capital Region
MedStar Franklin Square Medical Center	24	Central
Luminis Health Anne Arundel Medical Center	72	Central
Mercy Medical Center	72	Central
UMMS Central Stockpile	312	Central
Tidalhealth Peninsula Regional	72	Eastern Shore
Atlantic General Hospital	48	Eastern Shore
CalvetHealth Medical Center	48	Southern
Garrett Regional Medical Center	24	Western
UPMC Western Maryland	72	Western
Meritus Medical Center	48	Western
Total	888	

Notes:

[1] Adventist Healthcare sites each report a capacity of <10 per week, and as a system they may transfer product among hospitals as needed.

[2] UMMS supplying for 10 hospitals across Maryland

HHS suggests that allocations will be biweekly initially. Sites we allocate to cannot be changed in the early weeks of allocation because HHS wants to encourage consistency in site supply. Maryland operates a site-to-site transfer program to address areas that need additional supply, but we anticipate reduced demand due to the treatment indication for this particular product.

We anticipate that the 14 sites that receive allocation of Evusheld will be supplying 27 total sites across the state. The Therapeutics team anticipates that as product is utilized across the state, allocation will increase.

Allocations were submitted on December 12, 2021.

Hospital Providers with Evusheld

Note that "Satellite" locations operate under a "Hub" location.

